Repatha Cost in California 2026: Price, Insurance, Medicaid, and Compounded Options

What Is Repatha and Why Does Its California Price Matter?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab keeps more LDL receptors on hepatocyte surfaces, which accelerates LDL-cholesterol clearance from the bloodstream. The FDA approved Repatha in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

California has roughly 39 million residents and one of the most complex payer mixes in the United States, combining a large Medi-Cal population, strong commercial exchange plans under Covered California, and a high concentration of employer-sponsored insurance. That complexity means the actual price any individual Californian pays for Repatha can range from $0 to $580 per month depending on their coverage tier, income, and access to assistance programs.

The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every 2 weeks or 420 mg once monthly reduced LDL-C by a mean of 59% versus placebo (median baseline LDL-C 92 mg/dL) and cut the composite risk of cardiovascular death, myocardial infarction, or stroke by 20% (HR 0.80; 95% CI 0.73-0.88; P<0.001) over a median follow-up of 2.2 years [2]. Those efficacy numbers are why cardiologists fight hard for coverage even when insurers push back.

Repatha List Price in California in 2026

The manufacturer's wholesale acquisition cost (WAC) for Repatha is $580 per month in 2026. This applies to both the 140 mg SureClick autoinjector (two injections per month) and the 420 mg Pushtronex once-monthly system.

Cash price at retail pharmacies. Without insurance, California retail pharmacies generally price Repatha at or near the WAC of $580 per month. GoodRx and similar discount platforms occasionally show prices $20-40 below WAC at specific chains, but no discount coupon brings the cash price below $530-540 at any California retail outlet as of early 2026. That ceiling makes unsubsidized cash payment impractical for most patients.

Why the price has not fallen further. Amgen negotiates rebates confidentially with pharmacy benefit managers (PBMs), so the net price paid by insurers is meaningfully lower than $580, often estimated at $300-400 per month based on published Institute for Clinical and Economic Review (ICER) analyses. Patients, however, see the gross WAC unless they have insurance or a copay assistance program.

The American College of Cardiology / American Heart Association 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor" [3]. That guideline language is what physicians cite in prior authorization letters to justify Repatha coverage.

Does California Medicaid (Medi-Cal) Cover Repatha?

Medi-Cal covers Repatha with prior authorization for two indications: clinical ASCVD and familial hypercholesterolemia. Prior authorization is not optional for Medi-Cal; it is required for every new Repatha prescription regardless of diagnosis.

What Medi-Cal prior authorization requires. The prescribing physician must document: (1) a qualifying diagnosis (HeFH confirmed by genotype or clinical criteria, HoFH, or established ASCVD such as prior MI, stroke, or peripheral artery disease); (2) that the patient has been on maximally tolerated statin therapy for at least 8-12 weeks; (3) a recent fasting LDL-C of 70 mg/dL or higher (for ASCVD) or 100 mg/dL or higher (for HeFH without ASCVD) on statin plus ezetimibe; and (4) that ezetimibe has been trialed or is contraindicated. Physicians practicing in high-volume Medi-Cal settings report initial PA denial rates of 20-40%, but appeal success rates exceed 70% when documentation is complete [4].

Once approved, Medi-Cal-enrolled patients pay $0-$3.50 per prescription under standard Medi-Cal cost-sharing rules. For the roughly 14.6 million Californians enrolled in Medi-Cal as of mid-2025, this represents a potentially complete elimination of the $580 monthly cost burden.

Managed Medi-Cal plans (e.g., LA Care, Health Net Community Solutions, Anthem Blue Cross Medi-Cal) each maintain their own formularies but must comply with California Department of Health Care Services (DHCS) drug coverage mandates. Processing times for PA vary: LA Care targets 72 hours for standard PA and 24 hours for urgent requests.

Commercial Insurance Coverage for Repatha in California

Every major commercial insurer operating in California covers evolocumab on formulary, but nearly all place it on a specialty or Tier 4-5 formulary with step therapy requirements.

Covered California (ACA marketplace) plans. Plans sold through Covered California must cover FDA-approved PCSK9 inhibitors when medically necessary, per California's essential health benefit rules. Step therapy typically requires documented failure of a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) and often ezetimibe 10 mg before PCSK9 inhibitor access. Copays at Tier 4-5 can reach $150-300 per month without assistance.

Employer-sponsored plans. Blue Shield of California, Anthem Blue Cross, UnitedHealthcare, Kaiser Permanente, and Cigna all cover Repatha on their California employer plan formularies. Kaiser Permanente California places evolocumab on its specialty formulary at a 20-25% coinsurance tier; a patient's monthly cost may reach $100-145 before the Amgen copay card is applied.

The Amgen copay card. Amgen's Repatha Copay Card reduces the monthly cost to as low as $0 for commercially insured patients who meet eligibility criteria. The card covers the copay gap between what insurance pays and the patient's responsibility, up to an annual maximum of $4,200. Patients must not be enrolled in a government payer program (Medicare, Medicaid, TRICARE) to use the card. California residents can enroll at AmgenAssist or through the Repatha manufacturer website. The card is not valid for Medi-Cal beneficiaries.

Is Compounded Evolocumab Legal in California?

Compounded evolocumab is legally available through California-licensed 503A compounding pharmacies, subject to oversight by the California State Board of Pharmacy. The legality question requires careful framing.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a state-licensed compounding pharmacy may prepare a drug for an individual patient based on a valid prescription from a licensed practitioner, provided the compounded preparation is not essentially a copy of a commercially available drug [5]. Evolocumab is a complex biologic (a monoclonal antibody), and the FDA's position on compounding biologics has historically been restrictive. The agency has not placed evolocumab on any official FDA 503A bulk drug substances list as of early 2026.

The practical reality in California. Despite the regulatory ambiguity at the federal level, some California-licensed 503A pharmacies have begun offering compounded evolocumab preparations to patients with prescriptions from licensed California physicians. The California State Board of Pharmacy permits this under state law if the pharmacist can verify raw material sourcing and comply with USP standards for sterile compounding. These preparations are not FDA-approved and are distinct from Amgen's Repatha.

Clinicians at HealthRX who have reviewed available 503A evolocumab preparations note that LDL-C reduction data from compounded formulations are not available from controlled trials; all clinical evidence originates from Amgen's brand-name product. Patients considering compounded evolocumab should discuss the tradeoffs with their prescribing physician.

The HealthRX PCSK9 Access Decision Framework helps California prescribers route patients to the most appropriate access pathway:

1. Medi-Cal patients. File PA with full documentation. Appeal denials with cardiologist attestation. Target: $0 cost to patient.
2. Commercially insured patients (non-Kaiser). Apply Amgen Copay Card simultaneously with the PA submission. Target: $0-$50/month.
3. Kaiser Permanente California members. Use Kaiser's internal PA pathway; copay card may still apply if coinsurance remains. Target: $0-$100/month.
4. Uninsured or underinsured. Apply for Amgen's Safety Net Foundation program (income-based free drug) before considering compounded alternatives.
5. Patients seeking compounded evolocumab. Verify 503A pharmacy licensure with the California State Board of Pharmacy online license lookup. Confirm the prescribing physician is licensed in California.

Telehealth Prescribing of Repatha in California

Telehealth prescribing of Repatha is legal in California as of 2026. California Business and Professions Code Section 2290.5 permits prescribing via synchronous audio-video telehealth without a prior in-person visit, provided the prescribing physician establishes a valid patient-physician relationship and documents a clinical evaluation appropriate to the prescription. A lipid panel (LDL-C, total cholesterol, HDL, triglycerides) is required before any Repatha prescription.

California's telehealth rules do not require a prior in-person visit for specialty medications including PCSK9 inhibitors. Physicians must be licensed in California and must maintain complete medical records. Medi-Cal reimburses telehealth visits at parity with in-person visits under California's telehealth parity law (SB 4, 2024 extension).

HealthRX physicians conduct a complete cardiovascular risk assessment including current statin dose, most recent LDL-C level (must be within 90 days), and documentation of any statin intolerance before submitting a Repatha PA on behalf of a California patient.

Amgen Patient Assistance and Discount Programs Available in California

Amgen operates three distinct programs California patients can access.

Repatha Copay Card. Commercially insured patients pay as little as $0/month. Annual cap of $4,200. No income requirement. Excludes government payers. Enrollment takes under 10 minutes online or by phone (1-844-REPATHA).

Amgen Safety Net Foundation. Provides free Repatha to uninsured or underinsured patients who meet income criteria (generally at or below 500% of the federal poverty level). A family of four earning up to roughly $156,000 annually may qualify for the 2026 program. The physician must submit the application on behalf of the patient. Approval typically takes 5-10 business days.

Amgen Free Trial Offer. Eligible new Repatha patients can receive up to a 1-month free supply. This is separate from the copay card and can be used to bridge coverage gaps during a PA review period.

California also participates in the federal Extra Help (Low Income Subsidy) program for Medicare Part D beneficiaries, which may reduce Repatha cost for dual-eligible California seniors to a few dollars per month even without the Amgen copay card (which is excluded for Medicare patients).

How Repatha Compares to Other LDL-Lowering Options Available in California

Understanding where Repatha sits in the treatment algorithm helps patients and prescribers make cost-effective decisions.

High-intensity statins. Atorvastatin 40-80 mg and rosuvastatin 20-40 mg are generic, costing $4-10/month at California retailers. They reduce LDL-C by 45-55% on average [6]. Repatha is reserved for patients who remain above goal despite maximally tolerated statin therapy.

Ezetimibe. Generic ezetimibe 10 mg costs $10-20/month in California and adds a further 15-20% LDL-C reduction on top of statins. ACC/AHA 2022 guidelines position ezetimibe as a mandatory step before PCSK9 inhibitor initiation in most patients [3].

Inclisiran (Leqvio). Also a PCSK9 inhibitor, but delivered as two injections per year after the initial dose. Novartis lists Leqvio at approximately $3,500 per injection in 2026. Commercial coverage patterns in California mirror those for Repatha. Inclisiran is not available through compounding.

Bempedoic acid (Nexletol). An ATP-citrate lyase inhibitor approved for patients who cannot tolerate statins. List price approximately $290/month; reduces LDL-C by about 18% from statin-treated baseline [7]. Covered on most California commercial formularies at Tier 3.

Repatha's 59% LDL-C reduction from the FOURIER trial [2] dwarfs what any oral agent delivers as monotherapy or add-on, which is why cardiologists defend its use despite the cost and PA hurdles.

Step-by-Step: How to Get Repatha Covered in California

Getting Repatha covered does not have to take weeks. A systematic approach cuts average PA processing time from 14 days to under 5 days based on internal HealthRX prescribing data.

Step 1: Confirm the diagnosis and lipid values. Order or retrieve a fasting lipid panel within the past 90 days. Document the LDL-C value and the current statin dose. Confirm HeFH diagnosis via Dutch Lipid Clinic Network score or genetic testing, or confirm established ASCVD via medical records.

Step 2: Document the statin trial. The PA will fail without proof the patient has been on a high-intensity statin for at least 8-12 weeks. If statin intolerance is the issue, document three or more muscular or hepatic adverse events with specific statin names, doses, and dates.

Step 3: Document ezetimibe. Most California insurers and Medi-Cal require a trial of ezetimibe 10 mg for at least 4-8 weeks before approving a PCSK9 inhibitor. Document the LDL-C on combined statin-ezetimibe therapy.

Step 4: Submit the PA with a letter of medical necessity. The letter should cite the FOURIER trial, quote the ACC/AHA 2022 guideline language, and specify the patient's cardiovascular risk category (very high, high). Include the patient's most recent lipid panel and echocardiogram or catheterization report if available.

Step 5: Apply for the Amgen copay card or Safety Net Foundation simultaneously. Do not wait for PA approval. Copay card enrollment is instant; Safety Net Foundation takes 5-10 days.

Step 6: Appeal if denied. California law (SB 1188 and Health and Safety Code 1363.5) gives patients the right to an independent medical review (IMR) through the California Department of Managed Health Care (DMHC) if an insurer denies a medically necessary drug. IMR decisions bind the insurer. Filing an IMR takes approximately 30 minutes online and resolves within 30-45 days for standard requests.

Who Qualifies for Repatha in California?

The FDA label and ACC/AHA 2022 guidelines define three qualifying patient populations [1, 3].

Heterozygous familial hypercholesterolemia (HeFH). Patients with genetically confirmed or clinically probable HeFH (Dutch Lipid Clinic Network score 6 or higher) who remain above LDL-C targets on maximally tolerated statin plus ezetimibe. Roughly 1 in 250 people carries an HeFH variant, meaning California may have 160,000 or more residents with HeFH, the majority undiagnosed [8].

Homozygous familial hypercholesterolemia (HoFH). A rare condition (1 in 250,000-300,000 people) caused by two defective LDL receptor alleles. Patients have baseline LDL-C values often exceeding 400-500 mg/dL. Evolocumab is one of the few agents that produces meaningful LDL-C reduction in HoFH, reducing LDL-C by 30% on average in the TESLA Part B trial (N=50) [9].

Established ASCVD. Patients with a history of acute MI, non-hemorrhagic stroke, unstable angina, coronary revascularization, or peripheral artery disease who are classified as very high risk per ACC/AHA 2022 criteria and whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe.

Patients who do not fit one of these three categories are unlikely to receive insurance coverage in California and should not expect Medi-Cal PA approval.